Novoprotein(SH:688137) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-11-25 03:43Fundraising Overview - The company successfully completed its initial public offering (IPO) by issuing 17,543,860 shares at a price of RMB 106.19 per share, raising a total of RMB 186,298.25 million, with a net amount of RMB 174,219.58 million after deducting issuance costs [2][3] Fund Management and Usage - The company has established a special account for the raised funds, which is solely designated for the R&D center construction project and other related projects, ensuring that the funds are not used for any other purposes [6][20] - The balance in the special account as of November 11, 2025, is RMB 31,244.82 million, with additional accounts holding balances of RMB 8,000 million and RMB 9,972.27 million [11][15][20] Regulatory Compliance - The company has signed a tripartite supervision agreement with its wholly-owned subsidiary and the underwriting institution to ensure compliance with relevant laws and regulations, protecting investors' rights [4][26] - The underwriting institution is responsible for ongoing supervision of the fund usage, including conducting on-site investigations and providing regular account statements [7][27] Changes in Project Implementation - The company has approved changes to the implementation location of the R&D center project and has authorized the use of part of the raised funds for capital increase in its wholly-owned subsidiary to facilitate the project [3][30]